Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V41007 | PI-273 | 925069-34-7 | PI-273 is the first reversible and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor (antagonist) with IC50 of 0.47 μM. |
|
V41005 | PI3K/VEGFR2-IN-1 | 2851067-08-6 | PI3K/VEGFR2-IN-1 is a potent dual PI3K/VEGFR2 inhibitor (antagonist) with IC50s of 2.21 and 68 μM for inhibiting PI3K and VEGFR2, respectively. |
|
V54833 | Picrasidine I | 100234-59-1 | Picrasidine I is an anti-inflammatory and anti-osteoclastic dimeric alkaloid that can be extracted from Quassipsia quassipa. |
|
V41003 | Picrasidine Q | 101219-61-8 | Picrasidine Q is an alkaloid found in the angelica plant and has anti-cell transformation and anti-cancer effects. |
|
V41002 | Pifusertib hydrochloride (TAS-117 hydrochloride) | 2930090-28-9 | Pifusertib (TAS-117) HCl is a specific, orally bioactive allosteric Akt inhibitor (IC50 for Akt1, 2, and 3 are 4.8, 1.6, and 44 nM, respectively). |
|
V85780 | Pim-1 kinase inhibitor 10 | 2918764-57-3 | |
|
V54814 | Pinobanksin (3,5,7-Trihydroxyflavanone) | 548-82-3 | Pinobanksin causes apoptosis in B-cell lymphoma cell lines. |
|
V54910 | Pipermethystine | 71627-22-0 | Pipermethystine is an alkaloid extracted from the Kava plant. |
|
V54869 | Pipernonaline | 88660-10-0 | Pipernonaline is a piperine analogue with antiprostate cancer activity. |
|
V54811 | Pitavastatin-d4 (NK-104 d4) | 2070009-71-9 | Pitavastatin-d4 is the deuterium labelled form of Pitavastatin. |
|
V40997 | Pitstop 2 | 1419320-73-2 | Pitstop 2 is a clathrin inhibitor that can suppress clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin. |
|
V54975 | PK095 | 380314-37-4 | PK095 is a p53 mutant stabilizer. |
|
V40996 | Placulumab (ART621; CEP-37247; PN0621) | 945781-29-3 | Placulumab (ART621) is an anti-TNF alpha monoclonal antibody (mAb). |
|
V34731 | PND-1186 hydrochloride (VS-4718 hydrochloride; SR-2516 hydrochloride) | 1356154-94-3 | PND-1186 HCl (VS-4718 HCl) is a potent, specific, reversible FAK inhibitor (antagonist) with IC50 of 1.5 nM. |
|
V35006 | Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) | 31852-29-6 | Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of TLR3 and retinoic acid-inducible gene I receptors (RIG-I and MDA5). |
|
V56427 | Pomalidomide-d3 (CC-4047-d3) | 2093128-28-8 | Pomalidomide-d3 is the deuterated form of Pomalidomide. |
|
V40991 | POMHEX | 2004714-34-3 | POMHEX is a racemic mixture (racemate), an active POM precursor molecule of cell-permeable (penetrable) HEX, and a specific inhibitor of ENO2. |
|
V40987 | Pomstafib-2 | 2332841-83-3 | Pomstafib-2 is a potent and specific STAT5b inhibitor. |
|
V85939 | PRDX3(103-112) SO3 modified, human | 847447-04-5 | |
|
V86002 | PRDX3(103-112), human | 847447-01-2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
